Navigation Links
Takeda and Zinfandel Pharmaceuticals Initiate Phase 3 TOMMORROW Trial of AD-4833 for the Delay of Onset of Mild Cognitive Impairment Due to Alzheimer's Disease in Subjects Selected Using a Genetic-Based Biomarker Risk Assignment Algorithm
Date:8/26/2013

OSAKA, Japan and DURHAM, N.C., Aug. 26, 2013 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and its partner, Zinfandel Pharmaceuticals, Inc. ("Zinfandel"), today announced the initiation of TOMMORROW, a global Phase 3 clinical trial investigating a genetic-based biomarker risk assignment algorithm (risk assignment algorithm) to predict risk of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) within a five year period and to evaluate the efficacy of the investigational low dose pioglitazone (designated AD-4833 for this use) in delaying the onset of MCI due to AD in cognitively normal individuals at high risk as determined by the risk assignment algorithm.

The risk assignment algorithm is comprised of apolipoprotein E (APOE) and TOMM40 genotypes and age. Age and APOE genotype have previously been shown to indicate elevated risk of AD. The addition of TOMM40 is hypothesized to further refine the risk determination.

"To date, there have been a number of avenues investigated with the goal of altering the course of Alzheimer's disease but results have been unsuccessful," said Allen Roses, M.D., Chief Executive Officer, Zinfandel. "This is why the TOMMORROW trial is important. The potential to identify an individual's risk for developing MCI due to AD warrants further investigation."

AD is a devastating disease and diagnoses are increasing as the world's population ages. Currently 35.6 million people worldwide are living with some form of dementia. Studies show that individuals with MCI are at an increased risk of developing AD or another dementia with conversion rates of approximately 15 percent per year.

"AD-4833 is a member of a class of drugs known as PPAR (peroxisome proliferator-activated receptor)-gamma agonists which available data show may have a beneficial role in delaying symptoms of MCI due to AD," noted '/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Takeda Launches New Subsidiary in Peru
2. Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcerative Colitis and Crohns Disease
3. Among New Agents Entering the Unipolar Depression Market Over the Next Decade, Lundbeck/Takeda Pharmaceuticals Brintellix Has Blockbuster Potential
4. Takeda Submits Biologics License Application for a New Investigational Drug Vedolizumab, in Moderately to Severely Active Crohns Disease and Ulcerative Colitis in the United States
5. Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States
6. AGA Research Foundation Announces Endowment Gift from Takeda Pharmaceuticals U.S.A., Inc. to Support Gastroenterology Research
7. Takeda to Acquire Inviragen, Inc.
8. Takeda Responds to Verdict in Diabetes Drug Case
9. Takeda Launches New Subsidiary in Ecuador
10. Takeda lanza nueva subsidiaria en Ecuador
11. Scripps Research Institute and Takeda Pharmaceuticals Announce Expanded Research Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... Calif. , Oct. 17, 2014 A victim ... Orange County doctor with a history of alcohol ... ad for Yes on Prop 46 today, highlighting how Prop ... drug and alcohol testing. The ad pictures ... off reading "911-Report To ER."  Proposition 46 will enact the ...
(Date:10/17/2014)... , Oct. 17, 2014 The following ... Technology Policy: The Green Park Collaborative ... public and private payers, medical device and pharmaceutical ... other experts January 12, 2015 at its first ... of weight loss treatments.  Participants will discuss study ...
(Date:10/17/2014)... Oct. 17, 2014  UBM Medica US announces that ... endocrinologists and other clinicians who treat patients with ... effective use of insulin .  ... insulin replacement therapy – daily injections of one ... decline in the function of pancreatic beta cells. Insulin ...
Breaking Medicine Technology:Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 2Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 3Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 4Green Park Collaborative to Discuss Comparative Effectiveness and Value of Weight Loss Treatments 2Endocrinology Network Features Special Coverage on Effective Use of Insulin 2Endocrinology Network Features Special Coverage on Effective Use of Insulin 3
... June 2, 2011 Citeline, the world,s leading research ... a comprehensive review of clinical trial starts in the ... drug development. Over the one-year review period (October 2009 ... initiated in the oncology sector, more than any other ...
... June 2, 2011 PLC Systems Inc. (OTCBB: PLCSF), a ... it is preparing to commence the pivotal trial in the ... for sales and marketing in the U.S. from the U.S. ... Mark in the European Union. As part of ...
Cached Medicine Technology:Investment in Oncology Drug Development Remains Strong as 133 Companies Initiate Late-Stage Clinical Trials Representing a 21% Increase 2Investment in Oncology Drug Development Remains Strong as 133 Companies Initiate Late-Stage Clinical Trials Representing a 21% Increase 3PLC Ramps Up for U.S. Clinical Trial of RenalGuard® 2PLC Ramps Up for U.S. Clinical Trial of RenalGuard® 3
(Date:10/20/2014)... MA (PRWEB) October 20, 2014 ... sponsoring a booth at the American Foundation for Suicide ... 25th. The AFSP is a not-for-profit organization that hosts ... Net proceeds from these events are used to help ... but education and personal relationships as well. , ...
(Date:10/20/2014)... Zereana Jess-Huff, a 34-year-old mother, corporate executive and ... platform to think outside the bra. She doesn’t try to ... raise awareness about women’s other lady parts. , "We have ... the color pink and everybody knows what you’re talking about,” ... it has not been won when it comes to gynecologic ...
(Date:10/20/2014)... PA (PRWEB) October 20, 2014 ... Matthew Voicheck as Assistant Director of their ... role in managing the innovative turnkey drug sourcing, ... , Matthew brings over 12 years of industry ... joins Myoderm at the peak of their international ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Final Cut Pro ... release of the Citrus theme for FCPX filmmakers . ... use to describe the Citrus theme” Says Christina Austin, CEO ... to look so professional.” , Citrus comes with all the ... the template are: four transitions for added style, a title ...
(Date:10/20/2014)... 20, 2014 Do you ever feel ... comes a wonderful app Metassessor for teachers, specialists and ... helped its client “Intervention Development LLC” to launch ... is designed for iOS 4.3 or later and is ... is optimized for iPhone 5. It is now available ...
Breaking Medicine News(10 mins):Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 2Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 3Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3
... , SAN DIEGO, Dec. 15 "The entire San ... the passing of Sol Price on December 14, 2009. Mr. ... loyalty and ethics in his business, community and personal life. ... understood the responsibility of philanthropy and the role it plays ...
... , New Research Focuses on Unmarried Young Adults, Attitudes ... WASHINGTON, Dec. 15 Nearly all unmarried young adults ages 18-29 ... and 86% of women) and say that it is important to ... 88% of women), according to new research released by The National ...
... , ANN ARBOR, Mich., Dec. 14 Pepsi ... of Kentucky are among the major employers that implemented Thomson ... make better decisions about their benefits. , The Informed Enrollment ... of healthcare services and the cost of that care. With ...
... , , BRAINTREE, Mass., Dec. 14 Haemonetics Corporation ... filed a new legal action to stop Fenwal Inc.,s continued ... kits, using a modified separation chamber. Fenwal allegedly modified ... entered by the Court prohibiting Fenwal,s continued sale of infringing ...
... , , NAPA, Calif., Dec. 14 Tough Enough ... breast cancer, celebrated its fifth anniversary at the signature Tough ... Rodeo (Wrangler NFR) in Las Vegas. While pink is not ... western industry and rodeo fans was unmistakable as the sold-out ...
... ... , ... at Scripps Memorial Hospital La Jolla have elected Marc Sedwitz, MD, as the new chief of ... team on Jan. 1, 2010. , , , , ,During his two-year term, Dr. Sedwitz will ...
Cached Medicine News:Health News:San Diego Hospice and The Institute for Palliative Medicine on the Passing of Sol Price 2Health News:Although Most Unmarried Young Adults Want to Avoid Pregnancy, Many Don't Use Contraception, Know Little About It, and Think It Doesn't Make Much Difference 2Health News:Although Most Unmarried Young Adults Want to Avoid Pregnancy, Many Don't Use Contraception, Know Little About It, and Think It Doesn't Make Much Difference 3Health News:Corporations, Universities and State Governments Deploy Thomson Reuters Solution to Improve Employees' Benefit Selection Process 2Health News:Haemonetics Files a New Legal Action to Stop Fenwal Inc.'s Continued Patent Infringement 2Health News:Haemonetics Files a New Legal Action to Stop Fenwal Inc.'s Continued Patent Infringement 3Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 2Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 3Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 4Health News:New Chief of Staff Takes Over at Scripps Memorial Hospital La Jolla 2Health News:New Chief of Staff Takes Over at Scripps Memorial Hospital La Jolla 3
Test for determination of rheumatoid factor....
The SYNCHRON CX3 Delta is a critical care clinical system, providing unparalleled testing speed for the most frequently ordered chemistries-Glucose, BUN, Creatinine, Sodium, Potassium Chloride, CO2 C...
The Array 360 CEAL streamlines processes with computer enhancements and optimizes productivity by offering an exclusive design for aliquot samples....
Inquire...
Medicine Products: